Oculis HoldingOCS
OCS
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
61% more capital invested
Capital invested by funds: $36.9M [Q3] → $59.4M (+$22.4M) [Q4]
20% more funds holding
Funds holding: 10 [Q3] → 12 (+2) [Q4]
1.15% more ownership
Funds ownership: 7.22% [Q3] → 8.37% (+1.15%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$28
50%
upside
Avg. target
$33
75%
upside
High target
$41
120%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Chardan Capital Daniil Gataulin 27% 1-year accuracy 12 / 45 met price target | 50%upside $28 | Buy Maintained | 13 Mar 2025 |
Baird Colleen Kusy 19% 1-year accuracy 3 / 16 met price target | 120%upside $41 | Outperform Maintained | 13 Mar 2025 |
HC Wainwright & Co. Yi Chen 38% 1-year accuracy 64 / 167 met price target | 55%upside $29 | Buy Maintained | 13 Mar 2025 |
Financial journalist opinion
Based on 9 articles about OCS published over the past 30 days
Neutral
GlobeNewsWire
19 hours ago
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here.
Neutral
GlobeNewsWire
19 hours ago
Oculis to Host In-Person and Virtual R&D Day on Key Business Updates and the Development Plans for Privosegtor (OCS-05) in Acute Optic Neuritis and Beyond
ZUG, Switzerland, April 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that it will host an in-person and virtual R&D Day on Tuesday, April 15, 2025 from 10:00 AM to 12:00PM ET at the Intercontinental New York Barclay hotel. To register for the event, click here.
Neutral
GlobeNewsWire
1 week ago
Oculis Publishes Notifications of Transactions by Person Discharging Managerial Responsibilities
ZUG, Switzerland, March 20, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to trades entered into by a PDMR of the Company pursuant to a 10b5-1 trading plan, in accordance with Rule 10b5-1(c)(1) of the Securities Exchange Act of 1934, as amended.
Neutral
GlobeNewsWire
2 weeks ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, March 14, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to annual equity incentive awards granted to members of the executive committee of the Company, as well as purchase of ordinary shares by a member of the Company´s Board of Direcors.
Negative
Zacks Investment Research
3 weeks ago
Oculis Holding AG (OCS) Reports Q4 Loss, Misses Revenue Estimates
Oculis Holding AG (OCS) came out with a quarterly loss of $0.76 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.38 per share a year ago.
Neutral
GlobeNewsWire
3 weeks ago
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company's progress.
Neutral
GlobeNewsWire
3 weeks ago
Oculis Reports Q4 and Full Year 2024 Financial Results and Provides Company Update
ZUG, Switzerland, March 11, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company"), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced results for the quarter and full year ended December 31, 2024, and provided an overview of the Company's progress.
Neutral
GlobeNewsWire
3 weeks ago
Oculis to Present at Upcoming March Investor Conference
ZUG, Switzerland, March 05, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis will be attending and presenting at the following upcoming investor conference:
Neutral
GlobeNewsWire
4 weeks ago
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities
ZUG, Switzerland, March 03, 2025 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.
Neutral
GlobeNewsWire
1 month ago
Oculis Announces Pricing of $100 Million Oversubscribed Offering of Ordinary Shares
ZUG, Switzerland, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced the pricing of an underwritten offering of 5,000,000 of its ordinary shares, CHF 0.01 nominal value per share, at a price of $20.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses (the “Offering”).
Charts implemented using Lightweight Charts™